Haematologica, Vol 92, Issue 5, 719-720 doi:10.3324/haematol.10703
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishitsuka, K.
Right arrow Articles by Tamura, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ishitsuka, K.
Right arrow Articles by Tamura, K.

Acute Leukemia

Therapeutic potential of arsenic trioxide with or without interferon-{alpha} for relapsed/refractory adult T-cell leukemia/lymphoma

Kenji Ishitsuka*,, Junji Suzumiya*, Mikiko Aoki*, Kentaro Ogata°, Shuuji Hara°, Kazuo Tamura*

* 1st Department of Internal Medicine, Fukuoka University
° Department of Pharmacy, Fukuoka University Hospital

Correspondence: Kenji Ishitsuka, 1st Department of Internal Medicine, Fukuoka University, 7-45-1 Jonan-ku, Fukuoka, 814-0180, Japan. Phone: international +81.92.801.1011. Fax: international +81.92.865.5656. E-mail: kenjiishitsuka{at}fukuoka-u.ac.jp

Arsenic trioxide (As2O3) with or without interferon-{alpha} (IFN) was given to 4 patients with relapsed/refractory adult T-cell leukemia/lymphoma (ATLL). Treatment with As2O3 and IFN showed an encouraging response in two moderately-aggressive ATLL patients, while As2O3 alone was ineffective in two patients with very aggressive and rapidly progressing ATLL. Further studies are needed to clarify the role of As2O3 and its usefulness when combined with IFN for the treatment of ATLL.




This article has been cited by other articles:


Home page
 BMJ Case ReportsHome page
M.-O. Chandesris, D. Ghez, C. Besson, F. Suarez, R. Delarue, M.-T. Rubio, A. Bazarbachi, B. Varet, and O. Hermine
Complete remission of a relapsing adult T cell leukaemia following treatment of a secondary acute promyelocytic leukaemia: towards a reappraisal of arsenic trioxide and all-transretinoic acid?
BMJ Case Reports, August 10, 2009; 2009(aug10_1): bcr0120091449 - bcr0120091449.
[Abstract] [Full Text]

Home page
 BloodHome page
G. Kchour, M. Tarhini, M.-M. Kooshyar, H. El Hajj, E. Wattel, M. Mahmoudi, H. Hatoum, H. Rahimi, M. Maleki, H. Rafatpanah, et al.
Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL)
Blood, June 25, 2009; 113(26): 6528 - 6532.
[Abstract] [Full Text] [PDF]